A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
June 29, 2015DURECT to Present at the Cantor Fitzgerald Healthcare Conference
June 23, 2015DURECT Announces Plans for a New POSIDUR™ (SABERŽ-Bupivacaine) Clinical Trial
May 18, 2015DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study
April 30, 2015DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs